We are live on ! Find out more
IART icon

Integra LifeSciences

237 hedge funds and large institutions have $3.43B invested in Integra LifeSciences in 2020 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 84 increasing their positions, 84 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more call options, than puts

Call options by funds: $1.33M | Put options by funds: $987K

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

1.15% more ownership

Funds ownership: 85.14%86.29% (+1.1%)

1% more capital invested

Capital invested by funds: $3.39B → $3.43B (+$32.9M)

0% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 84

10% less funds holding

Funds holding: 264237 (-27)

54% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 50

Holders
237
Holders Change
-27
Holders Change %
-10.23%
% of All Funds
4.78%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.08%
New
23
Increased
84
Reduced
84
Closed
50
Calls
$1.33M
Puts
$987K
Net Calls
+$343K
Net Calls Change
+$2.19M
Name Holding Trade Value Shares
Change
Change in
Stake
PFA
151
Pure Financial Advisors
California
$506K
GC
152
Guggenheim Capital
Illinois
$505K +$152K +3,200 +43%
LPL Financial
153
LPL Financial
California
$480K +$79.1K +1,662 +20%
CNAM
154
Campbell Newman Asset Management
Wisconsin
$456K +$8.28K +174 +2%
AB
155
Amalgamated Bank
New York
$447K -$1.85K -39 -0.4%
P
156
Pitcairn
Pennsylvania
$429K -$12.6K -264 -3%
SF
157
Synovus Financial
Georgia
$417K +$13.7K +288 +3%
Osaic Holdings
158
Osaic Holdings
Arizona
$394K -$1.3M -27,323 -77%
Zurich Cantonal Bank
159
Zurich Cantonal Bank
Switzerland
$376K
OC
160
Oppenheimer & Co
New York
$374K +$126K +2,648 +50%
CT
161
Cambridge Trust
Massachusetts
$370K -$389K -8,175 -51%
Commonwealth Equity Services
162
Commonwealth Equity Services
Massachusetts
$362K +$40.2K +845 +12%
LWM
163
Loveless Wealth Management
Montana
$356K
X
164
Xponance
Pennsylvania
$351K +$50.9K +1,069 +17%
PPCM
165
Pillar Pacific Capital Management
California
$350K
WG
166
Winton Group
United Kingdom
$336K +$338K +7,113 New
PI
167
PEAK6 Investments
Illinois
$329K -$124K -2,599 -27%
SAM
168
Securian Asset Management
Minnesota
$325K -$12.3K -258 -4%
GT
169
Glenmede Trust
Pennsylvania
$305K +$15.4K +323 +5%
CGH
170
Crossmark Global Holdings
Texas
$300K -$951 -20 -0.3%
PAMU
171
Pictet Asset Management (UK)
United Kingdom
$293K +$295K +6,200 New
Parallax Volatility Advisers
172
Parallax Volatility Advisers
California
$291K +$293K +6,157 New
PA
173
Profund Advisors
Maryland
$290K +$292K +6,134 New
American Century Companies
174
American Century Companies
Missouri
$286K -$4.19K -88 -1%
GCP
175
GSA Capital Partners
United Kingdom
$286K +$288K +6,051 New

IART Hedge Fund Activity: Q3 2020 in Review

237 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q3 2020, worth a combined $3.43B — up 0.97% from $3.39B a quarter earlier.

Sellers outnumbered buyers: 50 funds closed out of IART and 23 opened new positions — a net loss of 27 holders — while 84 trimmed existing stakes and 84 added.

The largest buyer was Wellington Management Group, adding an estimated $114M. The largest seller was Vaughan Nelson Investment Management, exiting entirely with an estimated $44.6M sold.

  • 237 institutional investors held Integra LifeSciences (IART) as of Q3 2020, down from 264 in Q2 2020.
  • Funds reported $3.43B of Integra LifeSciences stock for Q3 2020, up 0.97% quarter-over-quarter.
  • 23 funds opened new Integra LifeSciences positions in Q3 2020 and 50 closed out, a net change of -27 holders.
  • The largest Integra LifeSciences buyer in Q3 2020 was Wellington Management Group, an estimated $114M added.
  • The largest Integra LifeSciences seller in Q3 2020 was Vaughan Nelson Investment Management, an estimated $44.6M sold.

Based on aggregated 13F filings for Q3 2020.